Table 3.
Case series and retrospective studies of AIs in the setting of recurrent, metastatic, or unresectable LGESS
| Study (y) | n | Age | ER/PR | Hormonal treatment | Response | Duration (mo) |
|---|---|---|---|---|---|---|
| Pink (2006)22 | 3 | 42‐69 | 3 +/+ | 3 Letrozole (2.5 mg/d) | 3 PR | – |
| Ioffe (2009)49 | 2 | – | – | 2 Letrozole | 1 PR, 1 SD | 53 |
| Dahhan (2009)57 | 1 | 53 | – | 1 Letrozole (2.5 mg/d) | PR | >4 |
| Yamaguchi (2015)17 | 5 | 36‐70 | 5 +/? | 5 Letrozole (2.5 mg/d) | 2 CR, 1 PR, 2 SD | – |
| Ryu (2015)10 | 13 | 42‐87 | 10 +/+ |
12 Letrozole (2.5 mg/d) 1 Aminoglutethimide (500 mg qid) |
5 CR, 6 PR, 2 PD | 4‐168 |
| First‐line therapy | 24 | AIs |
7 CR, 12 PR, 3 SD, 2 PD Effective rate: 91.7% |
|||
| Spano (2003)23 | 2 | 43‐53 | 2 +/+ |
1 Triptorelin → Aminoglutethimide (500 mg qid) 1 Aminoglutethimide +cortisol → Letrozole (2.5 mg/d) |
2CR | 84‐168 |
| Pink (2006)22 | 2 | 59‐69 | 2 +/+ | 2 Letrozole (2.5 mg/d) | 1 PR, 1 PD | – |
| Ioffe (2009)49 | 1 | – | 1 +/+ | 1 Letrozole | 1 PR | 124 |
| Dahhan (2009)57 | 2 | 47‐87 | – | 2 Letrozole (2.5 mg/d) | 1 PR, 1 PD | – |
| Altman (2012)13 | 4 | 28‐44 | – |
4 Anastrozole (1 mg/d) 1 Anastrozole (1 mg/d) → Letrozole (2.5 mg/d) 1 Anastrozole (1 mg/d) → Exemestane 25 mg/d |
3 SD, 1 PR | – |
| Ryu (2015)10 | 18 | 28‐63 | 10 +/+ |
9 Letrozole (2.5 mg/d) 7 Anastrozole (1 mg/d) 1 Aminoglutethimide (500 mg qid) 1 Exemestane 25 mg/d |
3 CR, 10 PR, 4 SD, 1PD | 3‐124 |
| Second‐line therapy | 29 | AIs |
7 CR, 13 PR, 6 SD, 3 PD Effective rate: 89.7% |
|||
| Total | 53 | AIs |
14 CR, 25 PR, 9 SD, 5 PD Effective rate: 90.6% |
CR, complete response; PD, progression of disease; PR, partial response; SD, stable disease; —, The data were not described clearly; →, It means a change from the former one to the latter one.
Effective rate: CR+PR+SD.